PMC:7288617 / 3840-3945 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T23","span":{"begin":21,"end":35},"obj":"Body_part"}],"attributes":[{"id":"A23","pred":"fma_id","subj":"T23","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"e use of intravenous immunoglobulin therapy. Fourteen days after the start of IVIG treatment, the patient"}

{"project":"LitCovid-PubTator","denotations":[{"id":"101","span":{"begin":98,"end":105},"obj":"Species"}],"attributes":[{"id":"A101","pred":"tao:has_database_id","subj":"101","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"e use of intravenous immunoglobulin therapy. Fourteen days after the start of IVIG treatment, the patient"}